A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics

Phase 1 Terminated 27 enrolled Aurigene Discovery Technologies Limited

NaSequentialOpen-labelTreatment

Summary

A Phase I, Open Label, Dose-Escalation, First in Human (FIH) study evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AUR103 Calcium in patients with relapsed advanced malignancies (BHARAT-1).

Timeline

Start: 2022-09-16
Primary completion: 2024-11-27
Completion: 2024-11-27

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AUR103	Unknown	25 mg	Oral
Subject	AUR103	Unknown	50 mg	Oral
Subject	AUR103	Unknown	100 mg	Oral
Subject	AUR103	Unknown	200 mg	Oral
Subject	AUR103	Unknown	400 mg	Oral

A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics

Summary

Timeline

Drugs

Indications